Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
about
Regulation of epithelial-mesenchymal transition by tumor-associated macrophages in cancerPlasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision MedicineInterleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expressionNo effect of NGAL/lipocalin-2 on aggressiveness of cancer in the MMTV-PyMT/FVB/N mouse model for breast cancerMicroenvironmental regulation of metastasisMacrophage diversity enhances tumor progression and metastasisPAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulationPhenotypic overlap between MMP-13 and the plasminogen activation system during wound healing in mice.Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice.Chemical glycosylation of cytochrome c improves physical and chemical protein stability.Micronutrient synergy--a new tool in effective control of metastasis and other key mechanisms of cancerPlasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescenceMouse models of breast cancer metastasis.Inhibition of pulmonary metastasis of melanoma b16fo cells in C57BL/6 mice by a nutrient mixture consisting of ascorbic Acid, lysine, proline, arginine, and green tea extract.Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cellsuPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.Extracellular proteolysis in transgenic mouse models of breast cancerThe ADAMTS1 protease gene is required for mammary tumor growth and metastasis.Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.Differential macrophage programming in the tumor microenvironment.Deregulation of paralogous 13 HOX genes in oral squamous cell carcinoma.Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy.Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo.Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background.Immune Regulation of the Metastatic Process: Implications for Therapy.Cell surface remodeling by plasmin: a new function for an old enzyme.Tumor-associated macrophages as major players in the tumor microenvironment.Overview of Genetically Engineered Mouse Models of Breast Cancer Used in Translational Biology and Drug Development.An Orthotopic Mouse Model of Spontaneous Breast Cancer Metastasis.Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in miceIn vivo and in vitro antitumor effect of a unique nutrient mixture on lung cancer cell line A-549.Inhibition of malignant mesothelioma cell matrix metalloproteinase production and invasion by a novel nutrient mixture.Antitumor effect of ascorbic acid, lysine, proline, arginine, and green tea extract on bladder cancer cell line T-24.Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation.Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway.D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR.Overexpression of Rab11-FIP2 in colorectal cancer cells promotes tumor migration and angiogenesis through increasing secretion of PAI-1.
P2860
Q26773786-E25B11BD-0213-4354-A774-A25219BD12DBQ28067626-D4A4FC31-5577-43FF-BB2C-CF5A5B9F6D34Q28390678-A77F3E97-F32D-4F83-815D-570ABDF58A32Q28480579-51C4DB3A-BD8B-4850-AA69-871D13D358FFQ29547660-4188166B-025A-4CFC-8B0E-1699AB136392Q29615847-2C69C8BC-A819-4AB0-A15C-16A9B6F457C2Q33782164-D8143AF9-0059-4D51-BBDB-002BEFA698C2Q33822269-C1A00456-ED4E-4BCE-A2E6-8E4D37A582BAQ33912224-519B4836-6957-4D7E-8935-0150F6FA0DC6Q34062756-9550459F-FE16-447D-A665-B26DBDD912A8Q34106007-5F751985-74E9-427E-BE74-08BCC32D6380Q34196515-F47BA416-374E-4245-81B7-8D698AC4E436Q34553964-03CA2460-08DC-41D1-B77A-E9BB303D0882Q34591134-4DF4E049-02E9-41F9-92B3-D6344BAEB364Q35050111-73D4E271-60B8-4B54-A3C0-AFDECB19879BQ35238060-5212261A-276F-4C18-92EE-9D9822BBC844Q35580701-97E712A7-53BE-48B2-8486-A38FABF34642Q35677095-CF2565F5-6DC2-4A6D-A9AE-2CD51266D750Q35679442-57FA15F5-9BBE-40C7-BC20-1A4A8F2C67ABQ35749341-466C14ED-6D13-4248-A436-4A044230E520Q35803027-29237409-DA26-4FFA-B61E-BC1733806BF6Q36309389-6F2BB759-F942-4FC9-8CB3-11D21206E06EQ36318551-1C1EFCB1-4968-46CD-8870-8A895849E237Q36485293-C28E14B1-5532-4BAA-A088-CFC49DDA4BB5Q37461337-62D80105-5B29-4641-94DE-0909086A3C6FQ37719488-6DABC74F-4512-4D94-BA60-3D7B95C1CC2AQ38055477-56627CC9-61B2-4938-BE78-83B4F82D279BQ38240110-6BD18336-EF9B-48F4-98AA-473B4011A9E3Q38578970-661CBE92-076E-4CA0-A871-414BB8EBC023Q38748700-74986600-1FC0-4886-90D3-B6A16AD29633Q39782448-D4669AA6-518F-40AB-A829-BA4EF9A3D088Q39842498-C6FBB5E8-55F1-4520-AF27-5871DF8F6F11Q40197719-2F0721DD-D10B-4C11-9338-6E78D416A40EQ40271366-6B4B2BB0-99B4-434E-AD42-90683375F16DQ40273810-F5BBBDD5-7C2B-4BF4-A1CD-5DD329F29C5EQ40293146-7278EDD0-830A-4815-85A2-F23605A85279Q40872425-C270AE85-2E18-439A-B227-859310E48AEBQ42136467-B306447A-58E8-4919-AFEF-3ADC9550B516Q48220228-1C419873-6763-4583-94B5-DC236D4BCE96Q52655258-4668E4C5-D458-40AC-8743-D6BF6AD89A5C
P2860
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
@ast
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
@en
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
@nl
type
label
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
@ast
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
@en
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
@nl
prefLabel
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
@ast
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
@en
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
@nl
P2093
P356
P1476
Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
@en
P2093
Boye S Nielsen
John Rømer
Jørgen Rygaard
Kasper Almholt
Leif R Lund
Morten Johnsen
P304
P356
10.1002/IJC.20631
P577
2005-02-01T00:00:00Z